Introduction:
The biosimilars market in India is experiencing rapid growth, driven by factors such as increasing demand for cost-effective alternatives to biologics and a favorable regulatory environment. According to a recent report by XYZ Research, the biosimilars market in India is projected to reach $X billion by 2026, with a CAGR of X%.
Top 20 Leading Biosimilars Brands in India 2026:
1. Biocon: Biocon is a leading Indian biopharmaceutical company that has established itself as a key player in the biosimilars market. With a market share of X%, Biocon’s biosimilars portfolio includes products such as Insulin Glargine and Trastuzumab.
2. Dr. Reddy’s Laboratories: Dr. Reddy’s Laboratories is another major player in the Indian biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Filgrastim and Rituximab.
3. Intas Pharmaceuticals: Intas Pharmaceuticals is a fast-growing player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Etanercept and Adalimumab.
4. Cipla: Cipla is a well-known Indian pharmaceutical company that has been making significant strides in the biosimilars market. With a market share of X%, Cipla’s biosimilars portfolio includes products like Pegfilgrastim and Bevacizumab.
5. Lupin: Lupin is a prominent player in the Indian biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Pegfilgrastim and Trastuzumab.
6. Glenmark Pharmaceuticals: Glenmark Pharmaceuticals is a key player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Pegfilgrastim and Bevacizumab.
7. Cadila Healthcare: Cadila Healthcare is a leading player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Filgrastim and Rituximab.
8. Sun Pharmaceutical Industries: Sun Pharmaceutical Industries is a major player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Insulin Glargine and Adalimumab.
9. Aurobindo Pharma: Aurobindo Pharma is a well-established player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Pegfilgrastim and Trastuzumab.
10. Zydus Cadila: Zydus Cadila is a key player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Filgrastim and Bevacizumab.
11. Emcure Pharmaceuticals: Emcure Pharmaceuticals is a growing player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Insulin Glargine and Rituximab.
12. Hetero Drugs: Hetero Drugs is a leading player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Etanercept and Trastuzumab.
13. Biocon Biologics: Biocon Biologics, a subsidiary of Biocon, is a significant player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Pegfilgrastim and Bevacizumab.
14. Torrent Pharmaceuticals: Torrent Pharmaceuticals is a major player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Insulin Glargine and Rituximab.
15. Wockhardt: Wockhardt is a well-known player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Filgrastim and Trastuzumab.
16. Alkem Laboratories: Alkem Laboratories is a prominent player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Pegfilgrastim and Adalimumab.
17. Panacea Biotec: Panacea Biotec is a key player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Etanercept and Bevacizumab.
18. Bharat Serums and Vaccines: Bharat Serums and Vaccines is a growing player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Insulin Glargine and Rituximab.
19. Reliance Life Sciences: Reliance Life Sciences is a significant player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products such as Filgrastim and Trastuzumab.
20. Jubilant Life Sciences: Jubilant Life Sciences is a major player in the biosimilars market, with a market share of X%. The company’s biosimilars portfolio includes products like Pegfilgrastim and Adalimumab.
Insights:
The biosimilars market in India is poised for continued growth in the coming years, driven by factors such as increasing healthcare expenditure, rising prevalence of chronic diseases, and a growing emphasis on cost-effective treatment options. According to XYZ Research, the biosimilars market in India is expected to witness a CAGR of X% between 2021 and 2026, reaching a market size of $X billion by the end of the forecast period. As more companies enter the biosimilars space and invest in research and development, competition is expected to intensify, leading to further innovation and expansion of the market. Overall, the future looks promising for the biosimilars market in India, with ample opportunities for growth and development.
Related Analysis: View Previous Industry Report
